Physician profile
Jerry G Back
NPI 1821181868
$322,096.47
in general payments reported to CMS, 2019-2025
54 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $48K · 2021: $66K · 2022: $74K · 2023: $6,508 · 2024: $324 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,180 · Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,180.00 |
| Food and Beverage | $843.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $101,443.82 | 2019-2024 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $46,970.06 | 2020-2024 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $45,402.45 | 2019-2022 | |
| Corcept Therapeutics | $43,874.25 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36,620.45 | 2021-2024 | |
| Novo Nordisk INC | $31,262.10 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $10,894.05 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,115.55 | 2019-2022 | |
| Amgen INC. | $383.97 | 2019-2024 | Repatha, Otezla |
| Valeritas, INC. | $334.37 | 2019 | |
| Abbvie INC. | $332.99 | 2019-2025 | Qulipta, Vraylar |
| Abbott Laboratories | $316.12 | 2021-2024 | Freestyle Libre, Eterna, Infinity |
| Avanir Pharmaceuticals, INC. | $260.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $258.65 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $175.25 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Back listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.